July 16, 2018
In July, there have been 8 sector positive closes, 1 negative and 1 holiday (45 covered companies) of 10 sessions – share pricing strength holds so far
It will be about exposure to market highs, geo-political and risk issues and possible sector rotation
I also find sentiment hazy!
Pre-open indications: 4 SELLs
RMi reports the pricing component of pre-open indications that shed light on share pricing events and its follow-on value!
Want to know WHY, subscribe!
July 6, 2018
For continued access to what one industry CEO calls the “Bible” for smart investing in the RegMed, gene and cell therapy sector, click on the button below:
http://www.regmedinvestors.com/create-account
Why spend time searching for sector news and analytics … it’s all right here!
Review daily indicators – pre-open and close, trends – whether they’re your friend or not, advance/decline lines of 45 covered companies, volatility responses followed by the factors involving decliners versus gainers and their daily percentages.
I “never leave an investor uninformed”
July 16, 2018
Infecting the sector …
Experts say the damage caused by Crispr has been 'seriously underestimated'
I have been saying – SELL for three (3) weeks as Intellia (NTLA) dives with fellow “mutators”. This is more than damaging, it’s an indictment!
Pre-open indications: 3 HIT and 1 MISS
Out and about: Shares of CRISPR gene-editing therapies plummeted after a study found that the technique can damage DNA. The research, published in the peer-reviewed journal Nature Biotechnology, is just the latest questioning whether the technique brings more benefit than harms to patients, with a report in June raising the possibility that edited cells could cause cancer.
I say today what others won’t, so you can do what others can’t!
Never leave an investor uninformed! Want to know WHY, WHAT and HOW, subscribe!
July 2, 2018
Reiterating from the pre-open’s newsletter … Mid-session, MDXG is DOWN -$2.23 or -34.90% to $4.16 after closing (Friday) at $6.39 and opening at $4.67
July 2, 2018
Cash keeps the doors open but, debt blossoms after Hercules tranche MESO opened at $5.62, is up +$0.249 or +4.54% to $5.748 after the session’s first hour
July 2, 2018
Stock opened at $13.12 had jumped $2.19 or +19.54% to $13.60 having seen a high of $14.50 However …
The process of calling out our grading of covered companies to rank and review the facts in evidence together with analysis, opinion and objective recommendation.
© 2018 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
